Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation: Results at 24 Months.

Trial Profile

Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation: Results at 24 Months.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs Everolimus (Primary) ; Azathioprine; Ciclosporin; Corticosteroids; Mycophenolic acid; Tacrolimus
  • Indications Heart transplant rejection; Heart-lung transplant rejection; Lung transplant rejection
  • Focus Adverse reactions
  • Acronyms NOCTET
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 14 Jun 2011 Results of the IVUS substudy published in Transplantation.
    • 16 Apr 2011 Tolerability results presented at the 31st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 21 Apr 2010 Tolerability and efficacy results presented at the 30th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top